Lead Sponsor

LEO Pharma

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

•Subjects must have signed and dated informed consent after receiving verbal and written information about the clinical trial.
•Subjects with unequivocal clinical diagnosis of moderate to severe scalp alopecia areata (patch type, totalis, universalis), as determined by the (sub) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline).
•Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit.
•Subject must accept to not cut hair in the treated scalp areas during the trial.

•Females who are pregnant or are breast feeding.
•Current signs of spontaneous hair regrowth.
•Diffuse type alopecia areata.
•Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig stage II and III)
•Subjects with changed or expected changes in medication for thyroid disease within 6 month before Visit 1 (screening) or during the trial.
•Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids, or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).

Related studies

NCT05398809 · Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata

NCT07029711 · Severe Alopecia Areata

NCT06826196 · Alopecia Areata (AA)

NCT05866562 · Alopecia Areata

NCT07136467 · Non-Segmental Vitiligo (NSV), Alopecia Areata, and more

LEO 124249 Ointment in the Treatment of Alopecia Areata